Sonoma Pharmaceuticals vs Vivos Therapeutics
Sonoma Pharmaceuticals and Vivos Therapeutics are similar in size: $19.5m and $17.4m of revenue in their latest fiscal years. Sonoma Pharmaceuticals grew faster (36.7% against 16.0%). Sonoma Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -16.3% against -121.4%.
| Latest fiscal year | Sonoma PharmaceuticalsSNOA, 2026 | Vivos TherapeuticsVVOS, 2025 |
|---|---|---|
| Revenue | $19.5m | $17.4m |
| Revenue growth | 36.7% | 16.0% |
| Net income | −$3.2m | −$21.2m |
| Operating margin | — | -114.1% |
| Net margin | -16.3% | -121.4% |
| Return on equity | -84.6% | — |
| Free cash flow | −$4.1m | −$17.6m |
| Cash | $2.4m | $2.0m |
| Total debt | $222,000 | $19.3m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 9 | 268 |
| Market value | $5.5m | $1.6m |
| Price vs our value range | — | — |
| Moat score | 26 (Weak) | 30 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 0 sales |